All In Biotech

Drug Trial Radar · NCT05518708

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

A Phase I Single-blind, Randomised, Placebo-controlled, Parallelgroup Design Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Harmacodynamics of Single Rising Doses of BI 3032950 Administered as Intravenous Infusion (Part A) or Subcutaneous Injection (Part B) to Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Sep 27, 2022

Primary completion

Sep 21, 2023

Study completion Sep 21, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B) administration of single rising doses.

Conditions

  • Healthy

Interventions

  • BI 3032950Drug

    BI 3032950

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with treatment-emergent adverse eventTime frame: Up to 116 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Life Science Services - Clinical Research

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.